Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract PO1-09-03: Clinical Impact of Multigene Panel Testing in Patients with a Personal or Family History of Breast or Ovarian Cancer Previously Negative for BRCA1/2 Genes

Devon Miller, Stephanie Pritzl, Angela Tess, Jessica Gooding, Lisa Barroilhet, Lori Dubenske, Kari Wisinski

Cancer Res (2024) 84 (9_Supplement): PO1-09-03.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-09-03

Published: 02 May 2024

View article titled, Abstract PO1-09-03: Clinical Impact of Multigene Panel Testing in Patients with a Personal or Family History of Breast or Ovarian Cancer Previously Negative for BRCA1/2 Genes

Journal Articles

Abstract 6395: Atovaquone promotes release of damage-associated molecular patterns from epithelial ovarian cancer cells

Mayra A. Betancourt Ponce, Nicha Boonpattrawong, Sejal Sharma, Jenny Gumperz, Manish Patankar, Lisa Barroilhet

Cancer Res (2023) 83 (7_Supplement): 6395.

https://doi.org/10.1158/1538-7445.AM2023-6395

Published: 04 April 2023

View article titled, Abstract 6395: Atovaquone promotes release of damage-associated molecular patterns from epithelial ovarian cancer cells

Journal Articles

Abstract 2845: Synthetic fusion cytokine, GIFT4, transduced autologous peritoneal immune cells - a novel cell therapy for the treatment of ovarian cancer

Sejal Tarun Sharma, Pradyut Paul, Rahul Das, Shala Yuan, Lisa Barroilhet, Jessica Vazquez, Aleksandar K. Stanic, Jacques Galipeau, Manish Patankar

Cancer Res (2022) 82 (12_Supplement): 2845.

https://doi.org/10.1158/1538-7445.AM2022-2845

Published: 15 June 2022

View article titled, Abstract 2845: Synthetic fusion cytokine, GIFT4, transduced autologous peritoneal immune cells - a novel cell therapy for the treatment of ovarian cancer

Journal Articles

Abstract 891: Plumbagin and atovaquone inhibit Na⁺/K⁺-ATPase through the generation of oxidative stress

Yousef Alharbi, Arvinder Kapur, Mildred Felder, Lisa Barroilhet, Bikash Pattnaik, Manish S. Patankar

Cancer Res (2019) 79 (13_Supplement): 891.

https://doi.org/10.1158/1538-7445.AM2019-891

Published: 01 July 2019

View article titled, Abstract 891: Plumbagin and atovaquone inhibit Na+/K+-ATPase through the generation of oxidative stress

Journal Articles

Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells

Molly J. Carroll, Kaitlin C. Fogg, Harin A. Patel, Harris B. Krause, Anne-Sophie Mancha, Manish S. Patankar, Paul S. Weisman, Lisa Barroilhet, Pamela K. Kreeger

Cancer Res (2018) 78 (13): 3560–3573.

https://doi.org/10.1158/0008-5472.CAN-17-3341

Published: 01 July 2018

View article titled, Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells

Includes: Supplementary data

Journal Articles

Abstract 5460: Targeting tumors by inhibiting mitochondrial electron transport

Arvinder Kapur, Amruta P. Nayak, Thomas Beres, Kavya Rathi, Mildred Felder, Amani Gillette, Spencer Ericksen, Melissa Skala, Lisa Barroilhet, Manish S. Patankar

Cancer Res (2017) 77 (13_Supplement): 5460.

https://doi.org/10.1158/1538-7445.AM2017-5460

Published: 01 July 2017

View article titled, Abstract 5460: Targeting tumors by inhibiting mitochondrial electron transport

Journal Articles

Abstract CT009: Targeting MUC16 with the THIOMAB^TM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

Joyce F. Liu, Kathleen N. Moore, Judy S. Wang, Manish Patel, Michael J. Birrer, Erika Hamilton, Lisa Barroilhet, William M. Flanagan, Yulei Wang, Amit Garg, Xuyang Lu, Anjali Vaze, Dilip Amin, Doug Leipold, S Renee Commerford, Eric W. Humke, Harold A. Burris

Cancer Res (2017) 77 (13_Supplement): CT009.

https://doi.org/10.1158/1538-7445.AM2017-CT009

Published: 01 July 2017

View article titled, Abstract CT009: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

NARROW

Abstract PO1-09-03: Clinical Impact of Multigene Panel Testing in Patients with a Personal or Family History of Breast or Ovarian Cancer Previously Negative for BRCA1/2 Genes

Abstract 6395: Atovaquone promotes release of damage-associated molecular patterns from epithelial ovarian cancer cells

Abstract 2845: Synthetic fusion cytokine, GIFT4, transduced autologous peritoneal immune cells - a novel cell therapy for the treatment of ovarian cancer

Abstract 891: Plumbagin and atovaquone inhibit Na⁺/K⁺-ATPase through the generation of oxidative stress

Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells

Abstract 5460: Targeting tumors by inhibiting mitochondrial electron transport

Abstract CT009: Targeting MUC16 with the THIOMAB^TM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

Email alerts

AACR Journals

Abstract PO1-09-03: Clinical Impact of Multigene Panel Testing in Patients with a Personal or Family History of Breast or Ovarian Cancer Previously Negative for BRCA1/2 Genes

Abstract 6395: Atovaquone promotes release of damage-associated molecular patterns from epithelial ovarian cancer cells

Abstract 2845: Synthetic fusion cytokine, GIFT4, transduced autologous peritoneal immune cells - a novel cell therapy for the treatment of ovarian cancer

Abstract 891: Plumbagin and atovaquone inhibit Na+/K+-ATPase through the generation of oxidative stress

Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells

Abstract 5460: Targeting tumors by inhibiting mitochondrial electron transport

Abstract CT009: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Abstract 891: Plumbagin and atovaquone inhibit Na⁺/K⁺-ATPase through the generation of oxidative stress

Abstract CT009: Targeting MUC16 with the THIOMAB^TM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study